(Q34451729)

2 August 2017

title

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial (English)

1 reference

2 August 2017

main subject

phase II clinical trial

0 references

placebo

0 references

Huntington's disease

0 references

author name string

Huntington Study Group Reach2HD Investigators

series ordinal

1

1 reference

2 August 2017

publication date

14 November 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

14

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

39-47

1 reference

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Intrinsic fluctuations within cortical systems account for intertrial variability in human behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Alterations in brain transition metals in Huntington disease: an evolving and intricate story

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

A novel approach to rapidly prevent age-related cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Unified Huntington's disease rating scale: Reliability and consistency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

HTRF analysis of soluble huntingtin in PHAROS PBMCs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Increased rate of suicide among patients with Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Are cognitive changes progressive in prediagnostic HD?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

A randomized, placebo-controlled trial of latrepirdine in Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

An evidence-based approach in the treatment of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970262-5

7 January 2021

10.1016/S1474-4422(14)70262-5

Identifiers

DOI

1 reference

2 August 2017

1 reference